Legend Biotech Corp

Legend Biotech Corp(LEGN)資訊與事件

$20.780

+0.941 (+4.53%)收盤時

LEGN 資訊

LEGN 事件

8/11 07:30

Legend Biotech Reports Q2 Revenue of $387.5M

Reports Q2 revenue $387.5M, consensus $351.75M. "Our second quarter results demonstrate the strength of our commercial and innovation engines at Legend Biotech," said Alan Bash, Interim Chief Executive Officer of Legend Biotech. "CARVYKTI continued to deliver growth as we expand patient access globally, including the most recent launch in Ireland, our 19th market. Commercial momentum of CARVYKTI provides the foundation to advance a diversified portfolio of next-generation cell therapies designed to expand the reach and impact of CAR-T. During the quarter, we achieved a significant innovation milestone with the first-in-human clinical readout for LB2501, validating our in vivo CAR-T platform. These advances demonstrate the breadth of our pipeline across hematologic malignancies and solid tumors and our commitment to bringing transformational cell therapies to patients beyond multiple myeloma. Our focus remains the same. Ensuring continuity across the business, maintaining strong execution, and advancing the strategic priorities that position Legend Biotech for long term growth. With meaningful commercial and clinical momentum and a strengthened balance sheet, we remain confident in our ability to advance innovation and progress toward company-wide profitability."

7/27 12:30

Legend Biotech Shares Drop 15.1% to $18.87

Legend Biotech is down -15.1%, or -$3.35 to $18.87.

7/27 10:30

Legend Biotech Shares Drop 12.5% to $19.45

Legend Biotech is down -12.5%, or -$2.77 to $19.45.

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

免費開始